Author

Sharon V. Barton

Observed names: S Barton, Sharon V Barton

Institution: GlaxoSmithKline (United Kingdom)

Observed institutions: GlaxoSmithKline (United Kingdom), GlaxoSmithKline Research & Development Limited (United Kingdom), University College London

OpenAlex ID: A5084847752

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

2015 · Duncan B. Richards, Louise M. Cookson, et al. · New England Journal of Medicine · 381

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis

2018 · Duncan B. Richards, Louise M. Cookson, et al. · Science Translational Medicine · 135

Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab

2015 · Isabelle J. Pouliquen, Oliver Kornmann, et al. · International Journal of Clinical Pharmacology and Therapeutics · 86

Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis

2015 · T Sahota, A Berges, et al. · CPT Pharmacometrics & Systems Pharmacology · 18

Extracellular volume with bolus‐only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time

2017 · Giulia Zumbo, Sharon V. Barton, et al. · Journal of Magnetic Resonance Imaging · 9

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

2015 · Mark B Pepys, Louise M Cookson, et al. · Blood · 4

Works count: 7

Citation count: 633

H-index: 5

I10-index: 4